Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease

The role of paclitaxel in the treatment of femoropopliteal peripheral arterial disease is currently ambiguous. A summary-level meta-analysis of randomised trials published in 2018 demonstrated that paclitaxel-coated devices were associated with an increased all-cause mortality in those who underwent...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ceazón T Edwards, Peter A Schneider, Cindy Huynh
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/a60b7e2b755e4b9aa004805cc787644a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a60b7e2b755e4b9aa004805cc787644a
record_format	dspace
spelling	oai:doaj.org-article:a60b7e2b755e4b9aa004805cc787644a2021-12-04T16:04:46ZPaclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease10.15420/ver.2020.142516-33022516-3299https://doaj.org/article/a60b7e2b755e4b9aa004805cc787644a2021-07-01T00:00:00Zhttps://verjournal.com/articleindex/ver.2020.14https://doaj.org/toc/2516-3299https://doaj.org/toc/2516-3302The role of paclitaxel in the treatment of femoropopliteal peripheral arterial disease is currently ambiguous. A summary-level meta-analysis of randomised trials published in 2018 demonstrated that paclitaxel-coated devices were associated with an increased all-cause mortality in those who underwent treatment at 2 years and 5 years. Further evaluation has been undertaken to establish whether there is a specific dose response, mechanism or reproducible signal. At this time, there has been no confirmation of dose response, as was initially asserted by the summary-level meta-analysis. No mechanism of harm has been identified. Although an association with increased mortality has been confirmed by patient-level meta-analysis, the strength of the signal has been inconsistent. The information suggests there is only an association between paclitaxel-coated devices and increased all-cause mortality, not causation. The authors encourage additional studies designed to follow long-term results after treatment with paclitaxel-coated devices, using real patient data, before a conclusion can be made.Ceazón T EdwardsPeter A SchneiderCindy HuynhRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENVascular and Endovascular Review , Vol 4, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Ceazón T Edwards Peter A Schneider Cindy Huynh Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease
description	The role of paclitaxel in the treatment of femoropopliteal peripheral arterial disease is currently ambiguous. A summary-level meta-analysis of randomised trials published in 2018 demonstrated that paclitaxel-coated devices were associated with an increased all-cause mortality in those who underwent treatment at 2 years and 5 years. Further evaluation has been undertaken to establish whether there is a specific dose response, mechanism or reproducible signal. At this time, there has been no confirmation of dose response, as was initially asserted by the summary-level meta-analysis. No mechanism of harm has been identified. Although an association with increased mortality has been confirmed by patient-level meta-analysis, the strength of the signal has been inconsistent. The information suggests there is only an association between paclitaxel-coated devices and increased all-cause mortality, not causation. The authors encourage additional studies designed to follow long-term results after treatment with paclitaxel-coated devices, using real patient data, before a conclusion can be made.
format	article
author	Ceazón T Edwards Peter A Schneider Cindy Huynh
author_facet	Ceazón T Edwards Peter A Schneider Cindy Huynh
author_sort	Ceazón T Edwards
title	Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease
title_short	Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease
title_full	Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease
title_fullStr	Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease
title_full_unstemmed	Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease
title_sort	paclitaxel exposure and dosage of drug-coated devices for the treatment of femoropopliteal peripheral artery disease
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/a60b7e2b755e4b9aa004805cc787644a
work_keys_str_mv	AT ceazontedwards paclitaxelexposureanddosageofdrugcoateddevicesforthetreatmentoffemoropoplitealperipheralarterydisease AT peteraschneider paclitaxelexposureanddosageofdrugcoateddevicesforthetreatmentoffemoropoplitealperipheralarterydisease AT cindyhuynh paclitaxelexposureanddosageofdrugcoateddevicesforthetreatmentoffemoropoplitealperipheralarterydisease
_version_	1718372691791052800

Paclitaxel Exposure and Dosage of Drug-coated Devices for the Treatment of Femoropopliteal Peripheral Artery Disease

Ejemplares similares